Cathie's Ark Logo
Verve Therapeutics Inc Logo

ARKG Holdings of Verve Therapeutics (VERV) - Updated Daily

Gene TherapyGenomicsCRSPR Gene Editing
Date
Direction
Shares
Fund Weight
Fund
July 7, 2023
BUY15.742k0.0143%ARKG
July 6, 2023
BUY19.998k0.0173%ARKG
June 28, 2023
BUY455.0000.0004%ARKG
June 27, 2023
BUY10.536k0.0093%ARKG
June 26, 2023
BUY19.676k0.0175%ARKG

Key Statistics

⚖️Weighting🧢Market Cap
2.13%$857.05m
🏋🏿‍♂️Weight Rank In ARKG🌏Country
20🇺🇸United States
🏋️‍♀️Weight Rank Across All Funds💳ARK Estimated Cost Average
35$37.81
🎫ARK Ownership Percent
4.42%
Description
verve therapeutics is a biotechnology company created with a singular focus: to protect the world from heart disease. the company brings together human genetics analysis and gene editing – two of the biggest breakthroughs in 21st century biomedicine – to develop transformative therapies for coronary heart disease. verve is developing medicines, administered once in life, to safely edit the genome of adults to permanently lower ldl cholesterol and triglyceride levels and thereby treat coronary heart disease. founded by world-leading experts in cardiovascular medicine, human genetics and gene editing, verve is backed by a top-tier syndicate of investors, including gv (formerly google ventures), arch venture partners, f-prime capital, biomatics capital, wellington management, casdin capital, and partners innovation fund. the company was recognized as a "2020 best places to work" by the boston business journal. verve is headquartered in cambridge, massachusetts.
Website
vervetx.com

Other ETFs That Hold VERV

Ticker
NameWeight
ARKGARK Genomic Revolution ETF2.46%
GNOMGlobal X Genomics & Biotechnology ETF1.1%
XBISPDR® S&P Biotech ETF0.82%
ARKKARK Innovation ETF0.36%
LABUS&P Biotech Bull 3X Shares ETF0.124%
IBBiShares Biotechnology ETF0.07%

Research Notes and Commentary for VERV

No Research Notes Found for VERV